Beijing GoBroad Boren Hospital｜Director Li Zhihui: Is Transplant Needed After CAR‑T Remission? Does TP53 Mutation Definitely Lead to Relapse?
Should patients receive a transplant after CAR‑T‑induced remission? When is the optimal timing? Is there hope for a second transplant? Will TP53 gene mutation inevitably result in relapse? These are frequent questions raised by parents of children with hematologic malignancies. In this session, Director Li Zhihui from Beijing Boren Hospital answers these key concerns one by one.
Q: Your team has rich experience in CAR‑T bridging allogeneic hematopoietic stem‑cell transplantation for malignant hematological diseases. Could you share which patients are recommended for bridging transplant after achieving remission via CAR‑T, and how patients can benefit?
Director Li Zhihui: One of CAR‑T’s greatest values is enabling some high‑risk, relapsed/refractory patients to achieve deep remission. However, remission does not equal cure.
Bridging allogeneic hematopoietic stem‑cell transplantation is actively considered for patients with multiple prior lines of therapy, early relapse, persistently‑positive MRD (minimal residual disease), high‑risk genetic features even with converted‑to‑negative MRD, and those for whom durable CAR‑T efficacy is unlikely. The core logic is: CAR‑T rapidly reduces tumor burden to achieve deep remission, then post‑transplant graft‑versus‑leukemia effect delivers long‑term disease control.
CAR‑T and transplantation are not mutually‑exclusive alternatives; instead, they complement each other. The critical step is assessing relapse risk and performing transplantation while the disease is in its best remission state, rather than waiting until subsequent relapse.
Q: Your publications note that optimal timing for post‑CAR‑T bridging transplant varies by disease type. What are the typical windows for B‑cell and T‑cell hematologic malignancies respectively, and what accounts for such differences?
Director Li Zhihui: There is no fixed number of days for post‑CAR‑T transplant timing. Decisions integrate disease biology, CAR‑T expansion persistence, bone‑marrow recovery, infection status and other clinical factors.
For B‑cell malignancies, particularly B‑ALL, transplantation is commonly performed 1‑2 months after MRD‑negative remission to allow patient recovery. T‑cell diseases progress faster with fewer salvage options upon relapse. Therefore we stress seizing the first remission window. For many T‑cell cases, bridging transplant can proceed as early as 2‑4 weeks once blood counts recover, infections are controlled and organ function permits.
In short: B‑cell diseases allow time to observe remission depth; T‑cell diseases demand urgency to avoid missing transplant opportunities.
Q: Patients relapsing after first‑time transplant are highly concerned about second‑transplant options. Drawing on your experience, which patients stand to benefit most from a second transplant? Your team strives for long‑term survival after second transplantation. Please share insights regarding donor selection, conditioning regimens and complication management.
Director Li Zhihui: A second transplant is not simply repeating the prior procedure. Patient screening for true benefit is paramount. Our research confirms that re‑achieving complete remission (CR) before second transplant strongly predicts long‑term survival. Our data also links TBI‑based conditioning to improved disease‑free survival (DFS) and overall survival (OS).
Prior to second transplant, we use chemotherapy, targeted agents or CAR‑T to regain disease control whenever feasible. The original donor is not mandatory; donors may be re‑selected according to relapse mechanisms, donor availability and the patient’s immunological profile.
Meanwhile, infection, GVHD and organ‑function monitoring require heightened vigilance. Second‑transplant success hinges not on transplant count itself, but comprehensive planning covering disease status, conditioning intensity and post‑transplant immune modulation.
Q: For patients with NK/T‑cell lymphoma, under what circumstances should allogeneic hematopoietic stem‑cell transplantation be considered, and what benefits can transplantation bring?
Director Li Zhihui: Not every NK/T‑cell lymphoma patient needs allogeneic transplant. Many early‑stage localized patients attain long‑term disease control with standard radiotherapy and L‑asparaginase‑containing regimens.
Allogeneic transplant is primarily indicated for advanced‑stage, high‑risk or relapsed/refractory patients who achieve CR or PR following systemic treatment including PD‑1 inhibitors.
For these patients, drug‑only therapy carries considerable relapse risk. Beyond high‑dose cytotoxic effects, allogeneic transplant generates sustained graft‑versus‑lymphoma activity. Its value lies in establishing a brand‑new immune system to pursue long‑term disease control or cure — not merely intensifying treatment. Again, transplant should ideally be performed while disease is well‑controlled.
Q: Your study accepted by Blood Advances shows superior prognosis among patients achieving complete or partial remission pre‑transplant. How should patients balance pursuing optimal remission and avoiding missed transplant windows caused by excessive prior treatment?
Director Li Zhihui: This represents a key clinical balance. Our research demonstrates distinctly better outcomes for patients in CR or PR before transplant compared with those with progressive disease. We aim to minimize tumor burden pre‑transplant, yet transplantation should not be delayed endlessly in pursuit of “perfect CR”.
If a solid CR or PR is attained, with improved PET/CT findings and decreased or undetectable EBV‑DNA, and further treatment is unlikely to deepen response significantly, the transplant workflow should commence promptly.
Repeated additional lines of therapy raise drug‑resistance risks, trigger infections, impair hepatic‑renal function and degrade physical performance, potentially disqualifying patients for transplant. My viewpoint: pursue the best achievable remission, but do not sacrifice the optimal transplant window chasing perfect remission.
Q: EBV infection and post‑transplant EBV reactivation impact patient prognosis. What experience has your team accumulated for pre‑ and post‑transplant prevention, surveillance and management of these risks? What should patients pay special attention to?
Director Li Zhihui: NK/T‑cell lymphoma is tightly associated with Epstein‑Barr virus. EBV‑DNA serves not only a virological marker but also an important indicator for tumor burden and relapse monitoring. We dynamically track EBV‑DNA alongside PET/CT scans and remission status before transplant. Regular EBV‑DNA surveillance continues early post‑transplant, especially for patients under heavy immunosuppression, receiving GVHD therapy or with rising viral loads.
We must distinguish tumor‑associated EBV from post‑transplant EBV‑driven B‑cell proliferative disease (PTLD). Rituximab targets PTLD rather than NK/T tumor cells. Persistently elevated EBV‑DNA calls for simultaneous evaluation for disease relapse, immunosuppression intensity and PTLD risk, with adjustments to immunosuppression, targeted therapies or cellular immunotherapy as needed. Patients should adhere to serial monitoring instead of fixating on a single test result.
Q: Studies associate TP53 mutation with elevated post‑transplant relapse risk. Does TP53 mutation guarantee relapse? What promising interventions can reduce risks and improve clinical outcomes?
Director Li Zhihui: TP53 mutation signals higher relapse risk, yet it does not equal inevitable relapse. It functions as a high‑risk alert that must be interpreted together with disease stage, treatment response, MRD, EBV‑DNA, additional genetic aberrations and pre‑transplant disease status.
Patients carrying TP53 mutations exhibit highly variable clinical trajectories. For this population, priorities include securing deeper pre‑transplant remission without missing transplant windows due to overtreatment, plus intensified post‑transplant surveillance via molecular testing, EBV‑DNA assays and imaging.
High‑risk patients may benefit from earlier prophylactic or pre‑emptive interventions such as immunotherapy, targeted agents or enrollment in clinical trials. No standard regimen fully eliminates relapse risk for TP53‑mutated disease. In our clinical practice, olaparib shows promising prophylactic effects lowering relapse rates for TP53‑mutated relapsed cases. Our practical strategy is early identification, early transplantation, close monitoring and timely intervention.
Comments